The Hormone You're Not Testing: How Prolactin Hijacks Male Sexual Function

When a man presents with erectile dysfunction and low testosterone, the standard workup measures testosterone, maybe LH and FSH, and then reaches for a prescription pad. Prolactin — the hormone most clinicians associate exclusively with lactation — rarely gets measured. This is a mistake that costs men years of misdiagnosis and failed treatments.

Hyperprolactinemia affects roughly 2–4% of men presenting with erectile dysfunction. That sounds rare. But here is the uncomfortable arithmetic: ED affects an estimated 30 million men in the United States alone. Two percent of 30 million is 600,000 men — and nearly all of them are treatable, often completely, with a medication that costs less than a dollar a day.

The problem is not that the treatment does not exist. The problem is that the test is not ordered.

The Double-Hit Model: How Prolactin Attacks Male Sexual Function

Prolactin does not simply lower testosterone. It attacks male sexual function through two independent pathways — a central mechanism in the brain and a peripheral mechanism in the penis itself. Understanding both explains why some men with hyperprolactinemia have devastating sexual dysfunction even when their testosterone levels look normal.

Hit #1: Central — Kisspeptin Suppression

The hypothalamic-pituitary-gonadal (HPG) axis depends on pulsatile GnRH secretion to drive LH release and, ultimately, testosterone production. The master switch for GnRH pulsatility is kisspeptin — a neuropeptide produced by specialized neurons in the arcuate nucleus of the hypothalamus.

Prolactin directly suppresses kisspeptin neurons. This is not speculation — it was proven causally in a landmark eLife study by Hackwell and colleagues (2024–2025). When they genetically deleted prolactin receptors specifically from arcuate kisspeptin neurons in mice, prolactin could no longer suppress LH pulsatility. The kisspeptin neurons are the target — not a secondary relay, not a downstream effect, but the primary site where prolactin shuts down the reproductive axis.

This mechanism explains a crucial clinical finding: in men with hyperprolactinemia, you typically see low testosterone with low or inappropriately normal LH — the hallmark of central (secondary) hypogonadism. The pituitary is not broken; it is simply not receiving the kisspeptin-driven GnRH signal that tells it to secrete LH.

There is a hopeful corollary. In a human study by Chan and colleagues (2022, JCEM), intravenous kisspeptin administration restored LH pulsatility in men with hyperprolactinemia-induced hypogonadism. The downstream machinery is intact — only the kisspeptin signal is missing. This confirms that prolactin acts as a reversible brake on the axis, not a destructive force.

Hit #2: Peripheral — Direct Penile Impairment

This is the finding that changes everything about how we think about prolactin and ED.

In November 2025, Cheng and colleagues published a study in Toxicology and Applied Pharmacology that demonstrated for the first time that prolactin directly impairs erectile function through a testosterone-independent mechanism. Using a prolactinoma rat model, they showed that hyperprolactinemia suppressed the PI3K–Akt–eNOS signaling pathway in penile corpus cavernosum tissue — even when testosterone levels remained normal.

eNOS (endothelial nitric oxide synthase) produces nitric oxide in the penile vasculature. Nitric oxide triggers smooth muscle relaxation and blood flow — the physiological basis of erection. When prolactin suppresses eNOS via the PI3K–Akt pathway, erections fail at the tissue level, regardless of whether testosterone is normal.

Critically, bromocriptine (a dopamine agonist that lowers prolactin) restored eNOS expression and erectile function without changing testosterone levels. This means that for some men, treating hyperprolactinemia fixes their ED through a mechanism that has nothing to do with testosterone.

The Normal-Testosterone Trap

This double-hit model resolves a clinical puzzle that has confused urologists and endocrinologists for decades: why do some men with hyperprolactinemia have erectile dysfunction and hypogonadal symptoms when their testosterone is perfectly normal?

A 2025 study in PLOS ONE by Cheng and colleagues identified a distinct subset of men with idiopathic hyperprolactinemia who presented with classical hypogonadal symptoms — low libido, erectile dysfunction, gynecomastia — despite having normal testosterone levels. After dopamine agonist treatment normalized prolactin (average 7.8 months), symptoms improved significantly in most patients.

This matters because the treatment algorithm embedded in most clinical guidelines follows a testosterone-first branching logic. The AUA recommends measuring testosterone first; prolactin only gets checked if testosterone is low and LH is low or normal. The EAU goes slightly further, recommending prolactin measurement in the context of secondary hypogonadism with low desire. But neither guideline recommends routine prolactin measurement in all men with ED.

The result is a systematic blind spot: men whose prolactin is high enough to impair erectile function through the peripheral eNOS pathway — but not high enough to suppress testosterone through the central kisspeptin pathway — fall through the diagnostic cracks.

Who Recovers? The Data on Dopamine Agonist Treatment

When hyperprolactinemia is identified and treated, outcomes can be dramatic. But recovery is neither universal nor instantaneous, and the data reveal clear patterns in who does and does not recover.

The Recovery Timeline

The most comprehensive data comes from Constantinescu and colleagues (2024), who followed 97 men with prolactinomas treated with dopamine agonists. A second independent cohort of 29 men (Milioto et al. 2025) validated the key findings.

Several patterns emerge from this data. First, most recovery happens in the first 12 months — the jump from 50% to 54% between 12 and 24 months is minimal. Second, prolactin normalization matters enormously: men whose prolactin normalized had recovery rates nearly 15 percentage points higher at every timepoint. Third, and most sobering, over 30% of men who achieve prolactin normalization still do not recover their testosterone — even at two years.

Why Some Men Do Not Recover

Rudman and Shimon addressed this directly in their 2025 review in Vitamins and Hormones. Over 20% of men with prolactinomas will remain hypogonadal despite effective dopamine agonist therapy and prolactin normalization. They identify two mechanisms:

1. Reversible central suppression: Prolactin suppresses kisspeptin neurons, which suppresses GnRH pulsatility, which suppresses LH. When prolactin is lowered, the kisspeptin neurons recover. This is the mechanism behind the 69% recovery rate.
2. Irreversible structural damage: In large prolactinomas (macroadenomas), the tumor mass compresses and destroys gonadotroph cells in the anterior pituitary. Even when the tumor shrinks, the gonadotrophs do not regenerate. These men have permanent secondary hypogonadism — not from prolactin elevation, but from physical destruction of the cells that make LH.

Predicting Who Will Recover

The clinical predictors are now well-defined:

The 6-month testosterone checkpoint is particularly actionable. If a man’s testosterone remains below 7.4 nmol/L six months into dopamine agonist treatment, the probability of spontaneous recovery is very low. This is the point at which testosterone replacement should be considered — not as a concession, but as a rational response to likely irreversible pituitary damage.

Erectile Function Recovery

A 2025 Egyptian cohort study (n=50) demonstrated the potential when treatment works:

The Czech retrospective cohort (PMID 40929710, 2025) confirmed that every treated patient who achieved prolactin normalization showed improvement in IIEF-5 scores. The combined approach of dopamine agonist therapy plus PDE5 inhibitors was particularly effective — addressing both the endocrine cause and the vascular consequence simultaneously.

An important clinical detail: simply treating hyperprolactinemic men with testosterone replacement does not reliably fix their ED unless prolactin is also normalized. The ICSM 2024 consensus (published 2025) reported that among men with macroprolactinomas treated with cabergoline, 20% did not recover from hypogonadism — and 100% of these non-recoverers reported no improvement in sexual function. By contrast, over 90% of men who did recover their testosterone reported improved sexual symptoms.

The message is clear: you must treat the prolactin, not just the testosterone.

The Hidden Cause: Drug-Induced Hyperprolactinemia

Not all hyperprolactinemia comes from pituitary tumors. Some of the most common medications in modern medicine can raise prolactin to levels that produce clinical hypogonadism — and this iatrogenic cause is massively underrecognized.

Antipsychotics: The Biggest Offenders

Antipsychotics cause hyperprolactinemia through D2 receptor blockade in the tuberoinfundibular pathway. Dopamine is prolactin’s natural brake — when you block dopamine receptors, prolactin surges.

The numbers are staggering:

The clinical tragedy here is compounded. Men with schizophrenia or bipolar disorder are already at elevated risk for sexual dysfunction from their underlying condition. When their antipsychotic raises prolactin, their sexual dysfunction worsens — and the sexual dysfunction is a leading cause of medication non-adherence. The patient stops their antipsychotic, relapses psychiatrically, and the cycle continues. Monitoring prolactin and switching to a prolactin-sparing agent could break this cycle.

Other Medications

Antipsychotics are the most significant cause of drug-induced hyperprolactinemia, but they are not alone. Metoclopramide and domperidone (D2 antagonists used as antiemetics and prokinetics) can elevate prolactin substantially. Some older antidepressants and antihypertensives (methyldopa, verapamil) have also been implicated, though the effect is generally milder.

The common thread is always the same: any drug that reduces dopaminergic tone in the tuberoinfundibular pathway can raise prolactin. And elevated prolactin, through the double-hit model, can impair sexual function both centrally and peripherally.

The Guideline Gap

Given everything above, you might expect clinical guidelines to recommend routine prolactin measurement in men presenting with sexual dysfunction. They do not — at least not unconditionally.

Here is what the major guidelines actually say:

Every major guideline places prolactin measurement downstream of testosterone measurement. The logic: testosterone is low in the majority of clinically significant cases, so screen with testosterone first, then look for causes including prolactin.

This logic has three blind spots:

1. The normal-T trap: Men whose prolactin is high enough to impair erectile function via the peripheral eNOS pathway but not high enough to suppress testosterone via kisspeptin never trigger the guideline cascade.
2. The cascade is rarely completed: Even when testosterone is low, the workup often stops there. LH and prolactin are not measured; testosterone replacement is started empirically. The prolactinoma continues to grow undetected.
3. Medication-induced cases are invisible: In men on antipsychotics, sexual dysfunction is attributed to the medication itself or the psychiatric condition — prolactin is rarely checked even though it is the mechanism linking the drug to the dysfunction.

The actual frequency with which clinicians measure prolactin in men with ED is not well-studied — which is itself telling. A compilation of over 3,200 ED patients found marked hyperprolactinemia in only 0.76% — but this was in cohorts where prolactin was systematically measured. In routine clinical practice, where prolactin is rarely ordered, the detection rate is almost certainly lower.

What This Means

The prolactin story in male sexual function is a case study in diagnostic inertia. The science is clear:

• Prolactin attacks male sexual function through two independent pathways — central kisspeptin suppression and peripheral eNOS impairment.
• The peripheral pathway operates independently of testosterone, creating a diagnostic blind spot in testosterone-first algorithms.
• Treatment with dopamine agonists (cabergoline or bromocriptine) restores testosterone in approximately two-thirds of men and can improve erectile function even when testosterone is normal.
• Over 20% of men with prolactinomas will have persistent hypogonadism — identifiable at 6 months by the T < 7.4 nmol/L cutoff.
• Drug-induced hyperprolactinemia affects up to 70% of men on certain antipsychotics and is a modifiable cause of sexual dysfunction in a vulnerable population.

The fix is straightforward: measure prolactin. Not just when testosterone is low. Not just when LH is low. Measure it as part of a comprehensive initial workup for male sexual dysfunction. It is a single blood test that costs approximately $30–50 and can identify a condition that is almost always treatable.

For men already on testosterone replacement who have not responded as expected, prolactin measurement is especially important. If you are replacing testosterone in a man whose problem is actually hyperprolactinemia, the testosterone will not fix the ED — and you will have missed a potentially curable underlying cause.

The literature is no longer ambiguous on this point. The only remaining gap is clinical practice catching up to the science.

Sources